DXVX announced on the 8th that it will launch two products in March: the protein supplement ProTeinMate-Ofmom and the women-only probiotic FloraMate-Ofmom. Both products were developed by the Microbiome Research Institute and are produced by its subsidiary Korea Biopharm (GMP).
With this, Dx&Vx has entered the protein supplement market, which is growing to a scale of 340 billion KRW due to increasing demand from the younger generation for body shape management and from middle-aged consumers seeking balanced nutrient supplementation, as well as the women-only probiotic market worth over 100 billion KRW. Both products are planned to be launched in the Chinese market following Korea.
The newly launched protein supplement ProTeinMate features a balanced blend of animal and plant proteins in a 1:1 ratio, resulting in higher protein absorption compared to single blend products. Additionally, it contains a high amount of beta-casein and uses high-quality goat milk protein similar to breast milk, which does not cause digestive disorders and tastes good, making it suitable for the whole family, regardless of age or gender.
The women-only probiotic FloraMate is designed to enhance immunity, improve vaginal health, lipid metabolism, and chronic fatigue, and also has anti-inflammatory effects, helping to prevent and manage various diseases that occur in women. Notably, all strains used in this product are clinically verified. It is a complex probiotic product consisting of five strains: L. rhamnosus GG, which can simultaneously boost and regulate immunity; L. plantarum LB931, derived from the vaginal flora of healthy adult women and regulates vaginal probiotics; B. lactis HN019, which improves lipid metabolism and has anti-inflammatory effects; B. breve M16V, which enhances the immunity of breast milk; and L. rhamnosus HN001, which improves postpartum depression and increases immune markers in breast milk.
Both new products apply the SynterAct Technology, a European patented technology developed by the Italian AAT Research Institute of the Cori Group. When consumed with dairy products, the proliferation rate of beneficial bacteria increases more than 100 times, and the products exhibit high survival rates through the digestive tract and strong inhibition of pathogen adhesion to the intestines, thereby enhancing gut health and immunity. The AAT Research Institute is a microbiome-based drug and healthcare product R&D institute spun off from the Catholic University of Rome, led by the world-renowned probiotic expert Dr. Lorenzo Morelli.
Lee Yong-gu, CEO of Dx&Vx, stated, “We are focusing on developing products for prevention, treatment, and management throughout the life cycle by utilizing microbiome technologies and materials that can be commercialized early in our company pipeline.” He added, “With the launch of antibiotics, obesity, and metabolic disease drugs in Korea and China, along with the expansion of healthcare nutrition product lineups and online and offline distribution, we expect to maintain a quantum growth trend this year, doubling last year’s sales of 46.7 billion KRW, while also improving profitability.”
Meanwhile, Dx&Vx is distributing and selling not only obesity drugs and diet probiotics for women but also its self-developed infant & kids exclusive probiotic FormulaMate-Ofmom in the Korean and Chinese markets. The microbiome-based new concept Dx&Vx therapeutic adjuvants developed in Cori Italy are currently undergoing import customs clearance, and a total of 12 products focusing on immune enhancement, cold relief, digestive function, and cognitive improvement are scheduled to be sequentially launched starting in March.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
